- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Influence of the 340B Drug Pricing Program
Bruce Feinberg, DO; Scott Gottlieb, MD; and Ted Okon, MBA, discuss the intentions and overall impact of the 340B Drug Pricing Program on the healthcare industry.
Dr Gottlieb and Mr Okon explain that despite its good intentions, the 340B Drug Pricing Program is leading to consolidation between oncology practices and hospitals.
“A program that was meant to service hospitals that really did have diverse missions and really did service a lot of underprivileged patients has been exploited by hospitals that don’t necessarily have the same mission,” says Dr Gottlieb.
Dr Gottlieb discusses further how hospitals are exploiting the program to generate additional revenue. He also explains that this consolidation is forcing some patients to receive oncology care in a hospital setting, which is not always best. This consolidation drives up healthcare costs and can affect the overall quality of care for patients.
Mr Okon notes that specifically, disproportionate-share hospitals are affecting the success of the 340B Drug Pricing Program, and highlights figures that demonstrate the overall financial impact of this program in the oncology setting.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Liquid Biopsy Whole-Genome Sequencing Optimizes MRD Detection in DLBCL
April 13th 2024Using the newly created MAESTRO-Pool tool, whole genome sequencing revealed DNA that could be used to more effectively detect minimum residual disease (MRD) in patients who have diffuse large B-cell lymphoma (DLBCL).
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
NSAIDs vs bDMARDs: Sex Disparities in Treatment Initiation for Axial Spondyloarthritis
April 12th 2024New research examining treatment initiation patterns among patients with axial spondyloarthritis revealed significant sex-based disparities, shedding light on the process from diagnosis to therapeutic intervention.
Read More
